Please login to the form below

abiraterone

This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.

Janssen’s Erleada improves survival in certain advanced prostate cancer patients

Androgen inhibitor Erleada (apalutamide) is Janssen’s follow-up to its older, blockbuster prostate cancer drug Zytiga (abiraterone acetate), which has now been hit by the loss of patent protection and

Latest news

AZ/Merck's Lynparza improves survival in certain prostate cancers

In the key secondary endpoint of overall survival, Lynparza reduced the risk of death by 31% compared to enzalutamide or abiraterone. ... Lynparza is the only PARP inhibitor to demonstrate overall survival versus enzalutamide or abiraterone for men with
J&J gets EMA nod for wider use of Erleada in prostate cancer

Androgen inhibitor Erleada (apalutamide) is J&J’s follow-up up to big-selling prostate cancer drug Zytiga (abiraterone acetate), which has been hit by the loss of patent protection and
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

Johnson &Johnson’s Zytiga (abiraterone) or Pfizer’s Xtandi (enzalutamide).
Litigation concerns threaten to overshadow solid quarter at J&J

therapy Zytiga (abiraterone acetate).
Lynparza scores another positive phase 3 prostate cancer study

Zytiga (abiraterone acetate) or Pfizer’s Xtandi (enzalutamide).

More from news
Approximately 5 fully matching, plus 61 partially matching documents found.

Latest Intelligence

Deal Watch May 2016

outperforming J&J's Zytiga [abiraterone].
Taking a strategic approach

But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen
Pharma deals during October 2013

AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy
Interview: Cesar Rodriguez, Janssen

Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

RWE Blog 1: Real-world challenges and real-world data

Real-world patients treated with abiraterone for post-chemotherapy metastatic castration-resistant prostate cancer survived longer with shorter treatment duration compared with patients in clinical trials.
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

Abiraterone. Zytiga. Janssen. Treatment of patients with metastatic castration-resistant prostate cancer. .

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Account Management: Competitive Salary Offered

Senior Content Editor - Biotechnology: Salary TBC

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...